Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin
about
The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor designChemical Lectinology: Tools for Probing the Ligands and Dynamics of Mammalian Lectins In VivoSiglecs and immune regulationAntigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169PILR and PILR have a siglec fold and provide the basis of binding to sialic acidBiochemical characterization and crystal structure of a GH10 xylanase from termite gut bacteria reveal a novel structural feature and significance of its bacterial Ig-like domainNegative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9Glycan array screening reveals a candidate ligand for Siglec-8Analysis of the binding sites of porcine sialoadhesin receptor with PRRSV.From a library of MAG antagonists to nanomolar CD22 ligands.Sialoside analogue arrays for rapid identification of high affinity siglec ligandsOn-virus construction of polyvalent glycan ligands for cell-surface receptorsIn vivo targeting of B-cell lymphoma with glycan ligands of CD22.Colorful virus-like particles: fluorescent protein packaging by the Qβ capsid.In silico-aided design of a glycan ligand of sialoadhesin for in vivo targeting of macrophages.Click and pick: identification of sialoside analogues for siglec-based cell targetingLiposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas.On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7.High affinity sialoside ligands of myelin associated glycoprotein.TIM-1 acts a dual-attachment receptor for Ebolavirus by interacting directly with viral GP and the PS on the viral envelope.Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells.beta1-integrin mediates myelin-associated glycoprotein signaling in neuronal growth cones.Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.New Human CD22/Siglec-2 Ligands with a Triazole Glycoside.Sialic Acids on Varicella-Zoster Virus Glycoprotein B Are Required for Cell-Cell FusionHomomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking.Structures of the Streptococcus sanguinis SrpA Binding Region with Human Sialoglycans Suggest Features of the Physiological Ligand.Molecular modeling of methyl-α-Neu5Ac analogues docked against cholera toxin--a molecular dynamics study.CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffoldGlycan-targeted virus-like nanoparticles for photodynamic therapy.Photoaffinity probes for studying carbohydrate biology.Potent glycan inhibitors of myelin-associated glycoprotein enhance axon outgrowth in vitro.CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
P2860
Q24553353-0C525790-C9A8-4A19-BA04-3EB9D93CB5F7Q26800514-D2E9130A-5CBE-4528-8A7E-9798CBEE6AFAQ26992091-148F9ED8-762C-4455-BC10-5D920889CA1AQ27301034-49CDF567-BA0A-4896-A4AD-CE8B5055470AQ27683849-E7D3F3B9-F9E3-4B0F-A35D-A794EB8F061AQ27684876-ADBD4EE7-4A24-4D89-8210-7B690D0CA981Q28275490-9C97C378-E721-4B5E-A537-7BEBEDED9D5DQ28295084-A9D876B6-A7F1-4628-9DB8-2B8ED6B8B2C5Q30357027-94E9D9A0-A741-41CB-9B26-9A2811FF7CE2Q31032076-B31BC015-E8F2-4EF6-B7DB-FD20F3D30AA2Q33331437-75A21AF3-76CB-4ECE-86FE-AA984B4AEDDBQ33792591-BFA2505F-72BC-403D-9CD6-954906FFB798Q33931886-F995E697-2111-4C7E-8155-BDE81B070314Q34047594-B1FE0DC2-7516-4E06-BD82-FBD0D216B3AEQ34411323-14D514DC-B7E0-4151-BBEB-9B2348649AC1Q34434838-E230BF22-55F5-413A-89AC-E3B06C3AACE1Q34470480-AAD3301C-D41F-4AB2-80C2-31F670F41DC6Q34677175-F8E401C2-28EA-4E5F-BEB1-6E6A64E6A694Q35165362-F508A065-7522-4943-A589-4E0C24220052Q36220496-7D0A174C-F2D4-4AFC-8742-D75EAF5C02BEQ36760447-3287BF21-42CA-461E-B490-A55C9AB56C46Q36957049-FD2EE3EB-D07F-4F38-AAAC-46678DA38AF4Q38598881-5C969A56-883D-4682-AF5D-27775E62442AQ38709008-A1565517-A518-4914-B300-B6D8D9734E34Q38860689-648D1340-1800-4ECF-8B08-7111255AC8AEQ40330842-FFE53572-12DC-434C-827F-DDAD4572BE2EQ40522700-29DBBF8A-2AE0-4794-B11F-BE9172F596A7Q41443980-2435C516-6B69-474F-8736-530A3C96113AQ41791550-35CD23A3-B406-4859-B32E-65422A34D6E8Q42176367-E648A5F0-2605-465F-BBE9-5392DD099AC1Q42402462-FC1FC401-F7B2-4F77-BC4D-1BE5BE2A671DQ42851971-EC6FF77E-4DFF-49F8-846E-8429E614DEADQ54937363-BDF63A67-79BE-472F-BADE-59B635566BF8
P2860
Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Structure-guided design of sia ...... s in complex with sialoadhesin
@ast
Structure-guided design of sia ...... s in complex with sialoadhesin
@en
Structure-guided design of sia ...... s in complex with sialoadhesin
@nl
type
label
Structure-guided design of sia ...... s in complex with sialoadhesin
@ast
Structure-guided design of sia ...... s in complex with sialoadhesin
@en
Structure-guided design of sia ...... s in complex with sialoadhesin
@nl
prefLabel
Structure-guided design of sia ...... s in complex with sialoadhesin
@ast
Structure-guided design of sia ...... s in complex with sialoadhesin
@en
Structure-guided design of sia ...... s in complex with sialoadhesin
@nl
P2093
P1433
P1476
Structure-guided design of sia ...... s in complex with sialoadhesin
@en
P2093
E Yvonne Jones
Katsumi Maenaka
Nathan R Zaccai
Reinhard Brossmer
Sørge Kelm
Taeko Maenaka
P304
P356
10.1016/S0969-2126(03)00073-X
P577
2003-05-01T00:00:00Z